An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions

High-Risk and Oligometastatic Prostate Cancer

Interventions

DRUG

Apalutamide

apalutamide as neoadjuvant therapy

Trial Locations (1)

RECRUITING

zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Zhujiang Hospital

OTHER